Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients

  Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.

Read more

MPE AGM 2020 webinar series

As part of the educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM) 2020, which was cancelled due to the outbreak of the coronavirus infection, MPE is organising a Webinars series.

Read more
July

August 2026

September
MO
TU
WE
TH
FR
SA
SU
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
Events for 1st August
No Events
Events for 2nd August
No Events
Events for 3rd August
No Events
Events for 4th August
No Events
Events for 5th August
No Events
Events for 6th August
No Events
Events for 7th August
No Events
Events for 8th August
No Events
Events for 9th August
No Events
Events for 10th August
No Events
Events for 11th August
No Events
Events for 12th August
No Events
Events for 13th August
No Events
Events for 14th August
No Events
Events for 15th August
No Events
Events for 16th August
No Events
Events for 17th August
No Events
Events for 18th August
No Events
Events for 19th August
No Events
Events for 20th August
No Events
Events for 21st August
No Events
Events for 22nd August
No Events
Events for 23rd August
No Events
Events for 24th August
No Events
Events for 25th August
No Events
Events for 26th August
No Events
Events for 27th August
No Events
Events for 28th August
No Events
Events for 29th August
No Events
Events for 30th August
No Events
Events for 31st August
No Events